COMPASS Pathways Plc - American (CMPS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Care Facilities) last closed at $14.01. The rating moved from Overbought to Neutral on August 19, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$14.01
• Last changeMoved from Overbought to Neutral on August 19, 2026
• SectorHealthcare
• IndustryMedical Care Facilities

AI analysis

COMPASS Pathways is a clinical-stage developer of psilocybin-based therapy with meaningful upside tied to clinical and regulatory milestones. Near-term performance will be driven by trial readouts, cash runway and financing activity. Biotech sector dynamics — including elevated M&A multiples — provide a potential valuation floor if development progresses, but the stock remains sensitive to binary trial outcomes, regulatory timing and dilution risk. Absent fresh company-specific news in the observed window, investors are likely to trade the name around upcoming catalysts and broader biotech sentiment.

Key factors

• Clinical-stage lead program in psilocybin therapy targeting treatment-resistant depression — potential large addressable market if Phase results and regulatory path are positive
• Sector valuation tailwinds and elevated biotech/Pharma M&A multiples that can support strategic interest or premium takeout
• Limited near-term macro or sector headlines within the last four hours, leaving focus on company-specific clinical and financing updates
• Partnership and CRO/CDMO demand thematic supports outsourced development and scale-up options for drug manufacturers and can benefit development timelines
• Current share price implies material upside relative to base-case M&A and successful trial scenarios, offering attractive risk/return for event-driven investors

Risks

• Clinical trial failure or inconclusive results for lead indications, which would materially reduce valuation
• Regulatory uncertainty around psychedelic therapies in major markets and potential delays in approval pathways
• Cash burn and financing risk — company may need to raise capital at dilutive levels if trial timelines extend
• Reimbursement, payer acceptance, and commercial rollout complexity for a novel therapy could limit near-term revenue realization
• Competition from other psychedelic developers, novel neuromodulation approaches, and conventional antidepressant improvements
• Operational or supply-chain constraints at CROs/CDMOs that could slow development and increase costs

Latest MarketMoodz coverage

• Trump Fast-Tracks Psychedelics for PTSD and Depression2026-05-31
• Newsom's Two-Word Reply Signals Friction Over Trump's Psychedelic Push2026-04-21
• Trump Order Triggers Rally in Psychedelic Stocks; Oppenheimer Sees Upside2026-04-20
• COMPASS Pathways Rally Sparks Investor Frenzy in Depression Drug2026-02-17

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.